Cargando…
Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
Preclinical studies have suggested that sunitinib accelerates metastases in animals, ascribing this to inhibition of the vascular endothelial growth factor receptor or the tumor’s adaptation. To address whether sunitinib accelerates tumors in humans, we analyzed data from the pivotal randomized phas...
Autores principales: | Blagoev, Krastan B., Wilkerson, Julia, Stein, Wilfred D., Motzer, Robert J., Bates, Susan E., Fojo, A. Tito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936322/ https://www.ncbi.nlm.nih.gov/pubmed/23395639 http://dx.doi.org/10.1016/j.celrep.2013.01.015 |
Ejemplares similares
-
Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example
por: Burotto, Mauricio, et al.
Publicado: (2014) -
Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer
por: Blagoev, Krastan B., et al.
Publicado: (2021) -
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010) -
Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status
por: Blagoev, Krastan B., et al.
Publicado: (2017) -
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)